EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
Search
Results for Jardiance EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
Our core product areas
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Animal Health Partnering Interests Infectious Diseases May 2024 CORP
Animal Health Partnering Interests Cardiometabolic Diseases May 2024 CORP
Animal Health Partnering Interests CNS Diseases May 2024 CORP
ACCESSIBLE_Stargardt_Disease
Stargardt_Disease
Cardiovascular renal and metabolic diseases infographic
Our_Inflammatory_Disease_Research.pdf
CardioMetabolic_diseases.pdf
Cardiometabolic_Diseases.pdf
Central_Nervous_System_Diseases.pdf
stargardt_disease_infographic.pdf
Partnering in Infectious Diseases MAY 2024 CORP_0.pdf
Chronic Obstructive Pulmonary Disease
Partnering in Cardiometabolic Diseases MAY 2023 Corp
Partnering in CNS Diseases MAY 2024 CORP_0.pdf
Partnering in Cardiometabolic Diseases MAY 2024 CORP_0.pdf
Cardiovascular Disease
The Global Cardiovascular Disease Burden.pdf
The Global Cardiovascular Disease Burden.pdf
Heart disease modulator
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development